Insight, China's Pharmaceutical Industry

Company

Novartis Q4 Results Show Growth in Innovative Medicines Amid Sandoz Spin-Off Plans

Swiss pharmaceutical giant Novartis (NYSE: NVS) has released its financial results for Q4 and the...

Company Deals

Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme

Fineline Cube Jan 31, 2023

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...

Company

Abbott’s Q4 Sales Dip Amid COVID-19 Testing Decline, China Market Updates

Fineline Cube Jan 31, 2023

US-based Abbott (NYSE: ABT) released its Q4 2022 financial results last week, showing a 6.1%...

Company Drug

Kelun’s SKB264 Receives Breakthrough Therapy Designation for Lung Cancer

Fineline Cube Jan 31, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody-drug conjugate (ADC) SKB264,...

Company Drug

Hengrui’s Camrelizumab-Apatinib Combo Approved for Liver Cancer in China

Fineline Cube Jan 31, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...

Company Drug

Yiling Pharmaceutical’s G201-Na Accepted for Review by China’s NMPA for Prostate Cancer

Fineline Cube Jan 31, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...

Company Drug

Zhaoke Ophthalmology’s Cyclosporine A Eye Gel Nears Market Approval in China

Fineline Cube Jan 31, 2023

Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...

Company Drug

Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes

Fineline Cube Jan 31, 2023

Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III...

Company Drug

Beijing HSA Sets Price for Hainan Simcere’s COVID-19 Therapy SIM0417

Fineline Cube Jan 31, 2023

Beijing’s municipal Healthcare Security Administration (HSA) bureau has released details of the initial quote and...

Company Drug

Qilu Pharmaceutical’s Biosimilar Lucentis Accepted for Review by China’s CDE

Fineline Cube Jan 31, 2023

China-based Qilu Pharmaceutical has announced that its market approval filing for a biosimilar version of...

Company Drug

RemeGen’s Telitacicept Gains FDA Approval for Phase III Study in Myasthenia Gravis

Fineline Cube Jan 31, 2023

China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced receiving approval from the US...

Company Drug

Luye Pharma Gains CDE Approval for Goserelin Acetate Microspheres Clinical Study

Fineline Cube Jan 31, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving approval from the Center for Drug...

Company Deals

Enkang Pharma Secures Series B Funding for DRIPs-Targeted Cancer Therapy

Fineline Cube Jan 31, 2023

Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd, a developer of DNA replication-initiation proteins (DRIPs)-targeted drugs, has...

Company Deals Drug

CARsgen and Roche Partner on Clinical Study for Gastric Cancer Treatment

Fineline Cube Jan 31, 2023

China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a clinical cooperation...

Company

Zennova Pharmaceuticals Completes Phase 1 of Chengdu Manufacturing and R&D Center

Fineline Cube Jan 31, 2023

Zennova Pharmaceuticals Group, a contract manufacturing organization (CMO) with operations in New Jersey, US, and...

Company Deals

Tigermed Completes Acquisition of Croatia-Based CRO Marti Farm

Fineline Cube Jan 31, 2023

China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the completion of...

Policy / Regulatory

China Unveils Measures to Boost Foreign Investment in R&D Centers

Fineline Cube Jan 30, 2023

The Ministry of Commerce and Ministry of Science and Technology, with the agreement of the...

Company Drug

Haisco’s Prostate Cancer Drug HSK38008 and DPP-4 Inhibitor HSK7653 Accepted for Review

Fineline Cube Jan 30, 2023

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for...

Company Deals

RemeGen and Allist Partner to Assess ADC and EGFR Inhibitor Combination in NSCLC

Fineline Cube Jan 30, 2023

China-based RemeGen Ltd (HKG: 9995) and Allist Pharmaceuticals Inc. (SHA: 688578) have announced a clinical...

Company Drug

HealZen Therapeutics Gains NMPA Approval for HZ-A-018 Clinical Study in Autoimmune Diseases

Fineline Cube Jan 30, 2023

Hangzhou-based HealZen Therapeutics has announced receiving approval from the National Medical Products Administration (NMPA) to...

Insight, China's Pharmaceutical Industry

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Novartis Q4 Results Show Growth in Innovative Medicines Amid Sandoz Spin-Off Plans

Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme

Abbott’s Q4 Sales Dip Amid COVID-19 Testing Decline, China Market Updates

Kelun’s SKB264 Receives Breakthrough Therapy Designation for Lung Cancer

Hengrui’s Camrelizumab-Apatinib Combo Approved for Liver Cancer in China

Yiling Pharmaceutical’s G201-Na Accepted for Review by China’s NMPA for Prostate Cancer

Zhaoke Ophthalmology’s Cyclosporine A Eye Gel Nears Market Approval in China

Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes

Beijing HSA Sets Price for Hainan Simcere’s COVID-19 Therapy SIM0417

Qilu Pharmaceutical’s Biosimilar Lucentis Accepted for Review by China’s CDE

RemeGen’s Telitacicept Gains FDA Approval for Phase III Study in Myasthenia Gravis

Luye Pharma Gains CDE Approval for Goserelin Acetate Microspheres Clinical Study

Enkang Pharma Secures Series B Funding for DRIPs-Targeted Cancer Therapy

CARsgen and Roche Partner on Clinical Study for Gastric Cancer Treatment

Zennova Pharmaceuticals Completes Phase 1 of Chengdu Manufacturing and R&D Center

Tigermed Completes Acquisition of Croatia-Based CRO Marti Farm

China Unveils Measures to Boost Foreign Investment in R&D Centers

Haisco’s Prostate Cancer Drug HSK38008 and DPP-4 Inhibitor HSK7653 Accepted for Review

RemeGen and Allist Partner to Assess ADC and EGFR Inhibitor Combination in NSCLC

HealZen Therapeutics Gains NMPA Approval for HZ-A-018 Clinical Study in Autoimmune Diseases

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories